Sudden death secondary to cardiac arrhythmias: Mechanisms and treatment strategies

Current Opinion in Cardiology

Volumn 21, Issue 5, 2006, Pages 517-525

  Siddiqui, Adnan ^a   Kowey, Peter R ^a,b  

^a LANKENAU HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Implantable cardioverter defibrillator; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; EPLERENONE; FISH OIL; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MORACIZINE; OMEGA 3 FATTY ACID; PRAVASTATIN; SOTALOL; SPIRONOLACTONE;

CARDIAC PATIENT; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; ISCHEMIC HEART DISEASE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SUDDEN DEATH; SURVIVAL RATE; TACHYCARDIA; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33747035300     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000240591.06839.39     Document Type: Review

References (100)

1. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol 2005; 28:I3-11.
2. Pinto DS, Josephson ME. Sudden cardiac death. In: Fuster V, editor. Hurst's the heart. New York: McGraw-Hill; 2001. pp. 1015-1048.
3. Zhi-Jie Zheng, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158-2163.
4. Goraya TY, Jacobsen SJ, Kottke TE, et al. Coronary heart disease death and sudden cardiac death: a 20-year population-based study. Am J Epidemiol 2003; 157:763-770.
5. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004; 109:2685-2691.
6. Centers for Disease Control. State-specific mortality from sudden cardiac death: United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 57: 123-126
7. Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated external defibrillators. N Engl J Med 2002; 347:1242-1247.
8. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345:1473-1482.
9. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 1997; 96:3215-3223.
10. Antezano ES, Hong M. Sudden cardiac death. J Intensive Care Med 2003; 18:313-329.
11. Engdahl J, Holmberg M, Karlson BW, et al. The epidemiology of out-of-hospital 'sudden' cardiac arrest. Resuscitation 2002; 52:235-245.
12. Engelstein ED, Zipes DP. Sudden cardiac death. In: Alexander RW, Schlant RC, Fuster V, editors. The heart, arteries and veins. New York: McGraw-Hill; 1998. pp. 1081-1112.
13. Lane RE, Cowie MR, Chow AW. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005; 91:674-680.
14. Epstein AE, Carlson MD, Fogoros RN, et al. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 1996; 27:433-442.
15. Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993; 88:2953-2961.
16. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117:151-159.
17. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98:2334-2351.
18. Wit AL, Janse MJ. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction. Circulation 1992; 85:I32-42.
19. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest 2005; 115:2305-2315. This paper provides an indepth explanation of the ionic imbalances and the subsequent generation of arrhythmias leading to SCD.
20. Owens LM, Fralix TA, Murphy E, et al. Correlation of ischemia-induced extracellular and intracellular ion changes to cell to-cell electrical uncoupling in isolated blood-perfused rabbit hearts. Circulation 1996; 94:10-13.
21. Spector PS. Diagnosis and management of sudden cardiac death. Heart 2005; 91:408-413.
22. Pogwizd SM, Corr PB. Mechanisms underlying the development of ventricular fibrillation during early myocardial ischemia. Circ Res 1990; 66:672-695.
23. Takahashi T, Van Dessel P, John C, et al. Optical mapping of the functional circuit of ventricular tachycardia in acute myocardial infarction. Heart Rhythm 2004; 1:451-459.
24. Echt D, Liebson P, Mitchell B, et al., and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial (CAST I). N Engl J Med 1991; 321:406-402.
25. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233
26. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270:1589-1595.
27. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1:1142-1147.
28. Waldo A, Camm J, deRuyter H, et al., for the SWORD Investigators. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction (SWORD: Survival With Oral D-sotalol). Lancet 1996; 348:7-12; Erratum in: Lancet 1996; 348:416.
29. Camm AJ, Pratt CM, Schwartz PJ, et al., on behalf of the AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109:990-996.
30. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333:77-82.
31. Ceremuzynski L, Kleczar K, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo controlled, pilot study. J Am Coll Cardiol 1992; 20:1056-1062.
32. Doval HC, Nul DR, Grancelli HO, et al., for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344:493-498.
33. Cairns J, Connolly S, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive premature depolarizations: CAMIAT. Lancet 1997; 349:675-682.
34. Julian D, Camm A, Frangin G, et al., for the European Myocardial Infarction Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674.
35. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
36. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality on survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). Lancet 1990; 16:1711-1718.
37. Sim I, McDonald K, Lavoir P, Norbutas B. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96:2823-2829.
38. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350:1417-1424.
39. Mirowski M, Reid P, Mower M, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989; 13:1353-1361.
40. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-1583.
41. Kuck KH, Cappato R, Siebels J, Rüppel R. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-754.
42. Connolly S, Gent M, Roberts R, et al., for the CIDS Investigators. The Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297-1302.
43. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996; 335:1933-1940.
44. Buxton AE, Lee KL, Fisher JD, et al., for the Multicenter Unsustained Tachycardia Trial investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341:1882-1890.
45. Bigger JT Jr, for the Coronary Artery Bypass Graft (CABG) Patch trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337:1569-1575.
46. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
47. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-2488.
48. Goldberger Z, Lampert R. Implantable cardioverter defibrillators: expanding indications and technologies. JAMA 2006; 295:809-818. This paper reviews the evolving indications and the advances in ICDs with emphasis on primary and secondary prophylaxis of SCD.
49. Kadish A, Dyer A, Daubert JP, et al., for the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151-2158.
50. Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005; 149:1020-1034.
51. Buxton AE. Identifying the high risk patient with coronary artery disease: is ejection fraction all you need? J Cardiovasc Electrophysiol 2005; 16:S25-S27. Comprehensively reviews predictive value of LVEF determination for ICD placements.
52. Kron J, Herre J, Renfroe EG, and the AVID Investigators. Lead and device related complications in the Antiarrhythmics Versus Implantable Defibrillator trial. Am Heart J 2001; 141:92-98.
53. Schron EB, Exner DV, Yao Q, et al. Quality of life in the Antiarrhythmics Versus Implantable Defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105:589-594.
54. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353:1471-1480. This paper reviews the cost effectiveness of the ICD in the populations represented in recent primary prevention trials.
55. De Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500-1505.
56. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687-697.
57. Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003; 42:652-658.
58. Barthel P, Schneider R, Bauer A, et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 2003; 108:1221-1226.
59. Gomes JA, Cain ME, Buxton AE, et al. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation 2001; 104:436-441.
60. Hohnloser SH, Ikeda T, Bloomfield DM, et al. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet 2003; 362:125-126.
61. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation 2004; 110:1885-1889.
62. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38:1902-1911.
63. Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol 2000; 36:2247-2253.
64. Bloomfield DM, Bigger JT, Steinman RC, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 47:456-463. Data in this prospective study have shown that TWA can help to identify a low-risk group unlikely to benefit from ICD therapy.
65. Gehi AK, Stein RH, Metz LD, et al. T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol 2005; 46:75-82. This meta-analysis demonstrates a significant value of TWA for the prediction of ventricular tachyarrhythmic events, though with limitations.
66. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al., for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22:1374-1450.
67. Freemantle N, Cleland JG, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 2001; 318:1730-1737.
68. CIBIS Investigators. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:1765-1773.
69. Packer M, Bristow MR, Cohn JR, et al., for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
70. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
71. CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999; 353:9-13.
72. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-1390.
73. Domanski M, Exner D, Borkowf C, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following a myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598-604.
74. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
75. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678-684.
76. Pfeffer MA, Braunwald E, Moye LA, et al., the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
77. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
78. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1122.
79. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685.
80. Ambrosioni E, Borghi C, Magnani B, the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332:80-85.
81. Kober L, Torp-Pedersen C, Carlsen JE, et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-1676.
82. Teo KK, Mitchell LB, Pogue J, et al., on behalf of the HOPE Investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure and left ventricular dysfunction. Circulation 2004; 110:1413-1417.
83. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
84. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
85. Covington M. Omega-3 fatty acids. Am Fam Physician 2004; 70:133-140.
86. Singh RB, Niaz MA, Sharma JP, et al. Randomized, double-blind, placebo controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian Experiment of Infarct Survival-4. Cardiovasc Drugs Ther 1997; 11:485-491.
87. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779-785.
88. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989; 2:757-761.
89. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-455.
90. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279:23-28.
91. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274:1363-1367.
92. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112:298-304.
93. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293:2884-2891. This recent trial has shown that fish oil supplementation does not reduce the risk of ventricular tachycardia or ventricular fibrillation and may be proarrhythmic in select patient groups.
94. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57:193-200.
95. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165:725-730. An extensive review of randomized controlled trials comparing any lipid-lowering intervention with placebo or usual diet with respect to mortality.
96. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
97. The Scandinavian Simvastatin Survival Study Group. Randomised trial for cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
98. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36:773-775.
99. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005; 95:490-491.
100. Riahi S, Schmidt EB, Christensen JH, et al. Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease. Cardiology 2005; 104:210-214.